OrthoPediatrics reports record Q2 revenue up 33% to $52.8M; net loss widens to $6.0M

ORTHOPEDIATRICS CORP

2024-Q2 EPS reported -$0.60 revenue$97,487,000

Q2 2024 revenue $52.8M (+33% YoY); U.S. +39%, Intl +16%. Trauma & Deformity +37%, Scoliosis +26%.
Net loss $6.0M ($0.26/share) vs $2.9M loss ($0.13) in Q2 2023; Adjusted EBITDA $2.6M vs $2.3M.
Reaffirmed FY2024 revenue guidance $200M-$203M (34-36% growth); EBITDA guidance $8M-$9M.
Announced $100M financing (term loan + convertible notes) from Braidwell LP; expects to close Aug 12, 2024.
Approved $5M stock buyback; cash $30.9M (down from $82.3M Dec 2023) due to $5.5M one-time payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.